Chain of Trust Project: Understanding patients and health professionals' perspective on Telehealth and building confidence and acceptance

Autor: Dr Michael Angastiniotis, Yiannis Konnaris, Neophytou, Haris, Dr Michael Wilks, Arias, Oscar Cano, Sarada Das, Liuska Sanna, Atzori, Walter, Knarvik, Undine, Halgeir Holthe, Jurate Svarcaite, Raeve, Paul De, Recio, Silvia Gomez

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6609aff36f6cfbf900148cbe2931d5cc

Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis

Autor: Patrick Garnero, Jacques P. Brown, T. Fashola, Ulrich Trechsel, Stefan Goemaere, Dieter Felsenberg, Jean-Pierre Devogelaer, Peter Burckhardt, C. E. Ortmann, Jean-Jacques Body, Erik Fink Eriksen, Joel S. Krasnow, Kurt Lippuner, Liuska Sanna, Pierre J. Meunier, Göran Samsioe

Publikováno v: Devogelaer, J P; Brown, J P; Burckhardt, P; Meunier, P J; Goemaere, S; Lippuner, K; Body, J J; Samsioe, G; Felsenberg, D; Fashola, T; Sanna, L; Ortmann, C E; Trechsel, U; Krasnow, J; Eriksen, E F; Garnero, P (2007). Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporosis international, 18(9), pp. 1211-8. London: Springer 10.1007/s00198-007-0367-3

In a 5-year study involving 119 postmenopausal women, zoledronic acid 4 mg given once-yearly for 2, 3 or 5 years was well tolerated with no evidence of excessive bone turnover reduction or any safety signals. BMD increased significantly. Bone turnove

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9dc05ca13091688b92c5345fe4dfeacc
https://pubmed.ncbi.nlm.nih.gov/17516022